Vallon Pharmaceuticals, Inc. (VLON) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Philadelphia, PA, 美国. 现任CEO为 David C. Baker.
VLON 拥有 IPO日期为 2021-02-10, 2 名全职员工, 在 NASDAQ Capital Marke.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
